Perrigo
PRGO
14.55
+0.55
+3.93%
Perrigo
US · PRGO
#2793 by market cap
Listed 1970
14.55
+0.55
+3.93%
Live - 5344 symbols - heartbeat 483s ago
· 2026-10-08 04:09
Pre-market
14.20
-2.41%
After-hours
14.55
0.00%
- Market cap
- 2.02B
- P/E (TTM)i
- -1.16
- P/Bi
- 0.80
- EPSi
- -10.29
- Div yieldi
- 7.97%
- 52W posi
- 51%
Reader sentiment
Are you bullish or bearish on PRGO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.48, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.75% YoY
Margins
- Gross margin
- 35.14%
- Operating margin
- 7.35%
- Net margin
- -33.51%
Key ratios & quality
- Enterprise valuei
- 5.13B
- Altman Z-Scorei
- 0.48
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.73B | 3.87B | 4.09B | 4.14B | 4.45B | 4.66B | 4.37B | 4.25B |
| Gross profit | 1.83B | 1.43B | 1.49B | 1.42B | 1.46B | 1.68B | 1.54B | 1.49B |
| Selling & admin expenses | 1.13B | 1.10B | 1.11B | 1.11B | 1.21B | 1.27B | 1.11B | 1.06B |
| Research & development | 218.60M | 119.20M | 121.70M | 122.00M | 123.10M | 122.50M | 112.20M | 95.40M |
| Operating profit | 481.90M | 214.40M | 268.40M | 600.40M | 121.40M | 284.10M | 311.90M | 312.80M |
| Pretax profit | 290.60M | 148.00M | 5.90M | 258.70M | -139.10M | -8.30M | -80.70M | -1.30B |
| Tax | 159.60M | -10.70M | -38.30M | 389.60M | -8.20M | -3.90M | 80.00M | 104.40M |
| Net profit | 131.00M | 146.10M | -162.60M | -68.90M | -140.60M | -12.70M | -171.80M | -1.43B |
| Basic EPS | 1 | 1 | -1 | -1 | -1 | 0 | -1 | -10 |
| Diluted EPS | 0.95 | 1.07 | -1.20 | -0.52 | -1.04 | -0.09 | -1.25 | -10.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.04B | 1.06B | 1.04B | 1.11B | 969.20M | 1.02B |
| Gross profit | 392.30M | 362.90M | 377.10M | 362.20M | 325.50M | 313.90M |
| Selling & admin expenses | 281.20M | 273.10M | 245.70M | 255.90M | 267.30M | 251.20M |
| Research & development | 26.70M | 22.00M | 24.90M | 21.80M | 24.60M | 23.70M |
| Operating profit | 79.40M | 55.60M | 93.40M | 84.40M | 33.60M | 39.00M |
| Pretax profit | 8.30M | 3.20M | 22.40M | -1.33B | -408.50M | 105.40M |
| Tax | 8.20M | 3.70M | 9.70M | 82.90M | -18.70M | 16.90M |
| Net profit | -6.40M | -8.40M | 7.50M | -1.42B | -398.50M | 74.40M |
| Basic EPS | 0 | 0 | 0 | -10 | -3 | 1 |
| Diluted EPS | -0.05 | -0.06 | 0.05 | -10.22 | -2.87 | 0.53 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.90B | 2.73B | 3.13B | 3.86B | 2.72B | 2.83B | 2.48B | 2.80B |
| Cash & ST investments | 551.10M | 354.30M | 631.50M | 1.86B | 600.70M | 751.30M | 558.80M | 531.60M |
| Inventory | 878.00M | 967.30M | 1.06B | 1.02B | 1.15B | 1.14B | 1.08B | 1.15B |
| Total assets | 10.98B | 11.30B | 11.49B | 10.43B | 11.02B | 10.81B | 9.65B | 8.54B |
| Total current liabilities | 1.54B | 1.34B | 1.38B | 1.59B | 1.11B | 1.59B | 1.04B | 1.01B |
| Short-term debt | 190.20M | 3.40M | 65.60M | 629.80M | 36.20M | 440.60M | 36.40M | 36.60M |
| Long-term debt | 3.05B | 3.37B | 3.53B | 2.92B | 4.07B | 3.63B | 3.58B | 3.60B |
| Total liabilities | 5,315,300,000.00 | 5,497,300,000.00 | 5,833,300,000.00 | 5,274,000,000.00 | 6,175,200,000.00 | 6,041,200,000.00 | 5,328,300,000.00 | 5,599,700,000.00 |
| Total equity | 5.67B | 5.80B | 5.66B | 5.15B | 4.84B | 4.77B | 4.32B | 2.94B |
| Retained earnings | -1.84B | -1.70B | -1.86B | -1.93B | -2.07B | -2.08B | -2.25B | -3.68B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 2.62B | 2.88B | 2.80B | 2.71B | 2.45B |
| Cash & ST investments | -- | 454.20M | 432.10M | 531.60M | 357.20M | 399.70M |
| Inventory | -- | 1.22B | 1.23B | 1.15B | 1.12B | 1.06B |
| Total assets | -- | 10.09B | 10.08B | 8.54B | 7.98B | 7.61B |
| Total current liabilities | -- | 1.13B | 1.15B | 1.01B | 997.60M | 1.05B |
| Short-term debt | -- | 36.40M | 36.60M | 36.60M | 11.40M | 11.40M |
| Long-term debt | -- | 3.62B | 3.61B | 3.60B | 3.62B | 3.28B |
| Total liabilities | -- | 5,621,800,000.00 | 5,637,500,000.00 | 5,599,700,000.00 | 5,484,500,000.00 | 5,093,700,000.00 |
| Total equity | -- | 4.47B | 4.45B | 2.94B | 2.50B | 2.52B |
| Retained earnings | -- | -2.27B | -2.26B | -3.68B | -4.08B | -4.00B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 593.00M | 387.80M | 636.20M | 156.30M | 307.30M | 405.50M | 362.90M | 238.50M |
| Depreciation & amortization | 423.60M | 396.50M | 384.80M | 312.20M | 338.60M | 359.50M | 325.90M | 337.50M |
| Free cash flow | 490.40M | 250.10M | 465.80M | 4.20M | 210.90M | 303.80M | 244.60M | 145.10M |
| Dividends paid | -104.90M | -112.40M | -123.90M | -129.60M | -142.40M | -149.70M | -152.50M | -159.30M |
| Stock buybacks / issuance | -398.70M | 900.00K | -164.20M | -- | -- | -- | -- | -- |
| Ending cash balance | 551.10M | 344.50M | 631.50M | 1.86B | 600.70M | 751.30M | 558.80M | 531.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | 75.90M | 51.70M | 175.40M | -113.60M | 82.60M |
| Depreciation & amortization | -- | 86.30M | 85.40M | 85.90M | 83.30M | 95.80M |
| Free cash flow | -- | 56.70M | 29.80M | 148.60M | -127.40M | 68.30M |
| Dividends paid | -- | -38.90M | -39.90M | -39.90M | -39.90M | -40.20M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | 454.20M | 432.10M | 531.60M | 357.20M | 399.70M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.21 | 2.55 | -2.84 | -1.28 | -2.81 | -0.26 | -3.78 | -39.29 |
| ROA %i | 1.16 | 1.31 | -1.43 | -0.63 | -1.31 | -0.12 | -1.68 | -15.68 |
| ROIC %i | 2.44 | 2.75 | -0.78 | 0.25 | 0.07 | 1.29 | -0.38 | -17.98 |
| 5-year avg ROE %i | -- | -- | -9.21 | 0.52 | -0.43 | -0.93 | -2.19 | -9.49 |
| EBIT margin %i | 8.90 | 6.01 | -0.48 | 9.27 | 0.38 | 3.55 | 2.45 | -26.70 |
| FCF / sales %i | 10.36 | 5.17 | 9.20 | 0.10 | 4.74 | 6.53 | 5.59 | 3.41 |
| Current ratioi | 1.89 | 2.04 | 2.27 | 2.43 | 2.44 | 1.79 | 2.38 | 2.76 |
| Quick ratioi | 1.06 | 1.20 | 0.89 | 1.59 | 1.17 | 0.94 | 1.15 | 1.13 |
| Debt / assetsi | 29.52 | 29.81 | 32.43 | 35.43 | 37.27 | 37.68 | 37.50 | 42.65 |
| LT debt / equityi | 53.85 | 57.99 | 64.72 | 59.48 | 84.06 | 76.19 | 82.92 | 122.76 |
| Interest coveragei | 3.23 | 2.43 | -0.20 | 3.07 | 0.11 | 0.95 | 0.57 | -6.99 |
| Revenue CAGR (3Y) %i | 3.27 | -9.84 | -6.15 | -4.37 | 4.78 | 4.43 | 1.86 | -1.51 |
| Net income CAGR (3Y) %i | -1.08 | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -10.31 | -23.04 | -8.61 | -79.54 | -5.52 | -13.28 | 287.62 | -11.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -1.78 | -1.15 | -39.29 | -52.97 | -49.65 |
| ROA %i | -- | -0.78 | -0.49 | -15.68 | -20.49 | -19.60 |
| ROIC %i | -- | 0.64 | 0.79 | -17.98 | -24.34 | -23.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | 6.53 | 6.21 | -26.70 | -37.11 | -34.97 |
| FCF / sales %i | -- | 5.93 | 6.34 | 3.41 | 2.58 | 2.88 |
| Current ratioi | -- | 2.32 | 2.51 | 2.76 | 2.72 | 2.32 |
| Quick ratioi | -- | 1.01 | 0.94 | 1.13 | 1.06 | 1.05 |
| Debt / assetsi | -- | 36.18 | 36.14 | 42.65 | 45.50 | 43.30 |
| LT debt / equityi | -- | 80.84 | 81.14 | 122.76 | 144.91 | 130.51 |
| Interest coveragei | -- | 1.58 | 1.64 | -6.99 | -9.44 | -8.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Self Care is the largest reported line at 56.38% of revenue, across 4 reported segments.
- Specialty Care follows at 22.16%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Self Care56.38%
Specialty Care22.16%
All other11.60%
Infant Formula9.87%
Quote time 2026-10-08 04:09:47 · For reference only, not investment advice and not tailored to your situation.